Fundamental analysis · SEC EDGAR · TTM through 31/03/2026
REGN · Nasdaq · Pharmaceutical Preparations
Fundamental quality
74
out of 100
Source: SEC EDGAR · TTM through 31/03/2026
On average over recent years, earnings per share grew 2.2% a year and revenue advanced 6.5% a year.
On profitability, Regeneron Pharmaceuticals, Inc. shows a net margin of 29.6%, an ROE of 14.1%.
Its financial health shows net debt of -0.23 times its EBITDA and a free cash flow margin of 27.6%.
Adding up growth, profitability and financial strength, the traffic light gives REGN a fundamental quality of 74 out of 100. To also know whether it's cheap or expensive, the price is missing: enter it in the tool and you'll get the valuation verdict (P/E against its sector).
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
Is Regeneron Pharmaceuticals, Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Brokers you can use to invest in U.S. and European stocks.
The serious investor's standard →
Popular in the U.S. →
Other analyses
NVIDIA (NVDA) · Microsoft (MSFT) · Apple (AAPL) · Alphabet (Google) (GOOGL) · Amazon (AMZN) · Meta Platforms (META) · see more →